SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76923.00
87.22 (0.11%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
61	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,773 Small Cap	4,692 (0.30%)	41.77	23.84	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
62	Jupiter Life Line Hospitals Ltd.	Q V PT	10,728 Small Cap	322.10 (-1.57%)	56.06	6.67	21.03	54.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
63	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	10,638 Small Cap	664.25 (-1.72%)	95.29	4.38	10.00	11.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
64	Healthcare Global Enterprises Ltd.	Q V+ PT	10,110 Small Cap	679.05 (0.28%)	693.42	6.3	13.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
65	Strides Pharma Science Ltd.	Q V+ PT	9,623 Small Cap	1,055.20 (1.07%)	52.4	2.93	3.25	-0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
66	Thyrocare Technologies Ltd.	Q V+ PT	9,287 Small Cap	592.20 (1.49%)	52.68	14.76	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
67	Suven Life Sciences Ltd.	Q V+ PT	8,807 Small Cap	297.85 (-4.44%)	N/A	5.02	-14.30	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
68	Yatharth Hospital & Trauma Care Services Ltd.	Q V PT	8,132 Small Cap	841.90 (-0.25%)	85.24	5.02	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
69	Sanofi India Ltd.	Q V PT	7,760 Small Cap	3,383.70 (0.43%)	25.05	9.95	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
70	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	6,974 Small Cap	211 (-1.81%)	4.49	5.23	49.34	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
71	Nephrocare Health Services Ltd.	Q V+ PT	6,853 Small Cap	689.80 (1.22%)	N/A	7.19	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
72	Supriya Lifescience Ltd.	Q V+ PT	6,799 Small Cap	833.30 (-1.36%)	32.51	5.68	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
73	FDC Ltd.	Q V PT	6,794 Small Cap	414.20 (-0.74%)	23.76	2.73	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
74	Senores Pharmaceuticals Ltd.	Q V+ PT	6,500 Small Cap	1,317.55 (-6.66%)	349.68	8.67	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
75	Kovai Medical Center & Hospital Ltd.	Q V PT	6,411 Small Cap	5,946.75 (1.51%)	26.22	4.86	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
76	Aarti Pharmalabs Ltd.	Q V+ PT	6,217 Small Cap	680.95 (-0.69%)	35.29	3.14	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
77	Innova Captab Ltd.	Q V PT	5,527 Small Cap	966.05 (0.02%)	66.04	6.23	25.90	14.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
78	Orchid Pharma Ltd.	Q V PT	5,002 Small Cap	986.40 (0.01%)	110.65	3.65	13.89	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
79	Bliss GVS Pharma Ltd.	Q V+ PT	4,898 Small Cap	450.60 (-2.26%)	50.56	4.28	9.41	4.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
80	RPG Life Sciences Ltd.	Q V+ PT	4,827 Small Cap	2,882.80 (-1.22%)	41.91	7.97	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
81	IOL Chemicals And Pharmaceuticals Ltd.	Q V+ PT	4,453 Small Cap	149.60 (-1.38%)	32.35	2.48	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
82	Artemis Medicare Services Ltd.	Q V PT	4,408 Small Cap	278.40 (-0.02%)	42.61	5.07	21.41	79.02	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
83	Novartis India Ltd.	Q V+ PT	4,023 Small Cap	1,614.10 (-0.92%)	41.14	4.73	-4.06	54.56	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
84	Gujarat Themis Biosyn Ltd.	Q V+ PT	3,930 Small Cap	356.25 (-1.22%)	84.18	13.66	12.12	15.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
85	Gufic Biosciences Ltd.	Q V PT	3,826 Small Cap	381.95 (0.10%)	60.59	5.76	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
86	Unichem Laboratories Ltd.	Q V PT	3,826 Small Cap	538.20 (-0.97%)	24.07	1.46	4.67	-173.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
87	Aarti Drugs Ltd.	Q V PT	3,752 Small Cap	409.40 (-0.40%)	19.25	2.42	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
88	SMS Pharmaceuticals Ltd.	Q V+ PT	3,662 Small Cap	382.60 (-2.15%)	41.8	4.55	13.70	14.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
89	Advanced Enzyme Technologies Ltd.	Q V PT	3,555 Small Cap	315 (-0.77%)	26.97	5.07	9.82	13.51	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
90	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,382 Small Cap	368.65 (-0.08%)	18.42	4.57	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.75	3.26%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	590.30	2.17%
Laurus Labs	1,745.85	1.84%
Cipla	1,434.80	1.77%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,121.05	-7.35%
Senores Pharmaceutic	1,317.55	-6.66%
Suven Life Sciences	297.85	-4.44%
Wanbury	318.55	-3.82%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

Senores Pharmaceutic - Quaterly Results

The turnover zoomed to Rs. 269.90 millions, up 67.33% for the June 2026 quarter as against Rs. 161.30 millions during the year-ago period.Net Profit of the company move down -61.85% to Rs. 10.30 millions from Rs. 27.00 millions in the same quarter last year.The company reported a degrowth in operating Profit to 72.20 millions from 72.30 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	269.90	161.30	67.33	269.90	161.30	67.33	1060.90	385.40	175.27
Other Income	95.50	120.80	-20.94	95.50	120.80	-20.94	663.50	219.90	201.73
PBIDT	72.20	72.30	-0.14	72.20	72.30	-0.14	476.70	147.10	224.07
Interest	22.20	17.60	26.14	22.20	17.60	26.14	69.80	65.20	7.06
PBDT	50.00	54.70	-8.59	50.00	54.70	-8.59	406.90	81.90	396.83
Depreciation	36.10	18.80	92.02	36.10	18.80	92.02	132.30	30.80	329.55
PBT	13.90	35.90	-61.28	13.90	35.90	-61.28	274.60	51.10	437.38
TAX	3.60	8.90	-59.55	3.60	8.90	-59.55	72.10	14.20	407.75
Deferred Tax	0.50	5.00	-90.00	0.50	5.00	-90.00	-12.40	-0.30	4033.33
PAT	10.30	27.00	-61.85	10.30	27.00	-61.85	202.50	36.90	448.78
Equity	460.54	460.54	0.00	460.54	460.54	0.00	460.50	460.50	0.00
PBIDTM(%)	26.75	44.82	-40.32	26.75	44.82	-40.32	44.93	38.17	17.73

Jul, 2026

SMS Pharmaceuticals informs about board meeting

SMS Pharmaceuticals has informed that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026, inter alia, to consider and approve Un-audited Financial Results of the Company for the first quarter ended on June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Akums Drugs’ arm gets nod to acquire Oriflame India’s manufacturing business

The said acquisition is expected to be completed by August 31, 2026

Jul, 2026

Novartis India - Quaterly Results

The June 2026 quarter revenue stood at Rs. 1038.10 millions, up 18.57% as compared to Rs. 875.50 millions during the corresponding quarter last year.A humble growth in net profit of 16.62% reported in the quarter ended June 2026 to Rs. 322.10 millions from Rs. 276.20 millions.The company reported a good operating profit of 436.50 millions compared to 378.50 millions of corresponding previous quarter.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	1038.10	875.50	18.57	1038.10	875.50	18.57	3543.30	3562.70	-0.54
Other Income	87.40	106.10	-17.62	87.40	106.10	-17.62	387.70	419.60	-7.60
PBIDT	436.50	378.50	15.32	436.50	378.50	15.32	1328.70	1333.80	-0.38
Interest	0.60	1.00	-40.00	0.60	1.00	-40.00	12.60	7.70	63.64
PBDT	435.90	377.50	15.47	435.90	377.50	15.47	1316.10	1326.10	-0.75
Depreciation	4.20	5.30	-20.75	4.20	5.30	-20.75	19.50	21.90	-10.96
PBT	431.70	372.20	15.99	431.70	372.20	15.99	1296.60	1304.20	-0.58
TAX	109.60	96.00	14.17	109.60	96.00	14.17	364.80	295.20	23.58
Deferred Tax	-5.00	0.00	0.00	-5.00	0.00	0.00	15.30	-4.40	-447.73
PAT	322.10	276.20	16.62	322.10	276.20	16.62	931.80	1009.00	-7.65
Equity	123.40	123.40	0.00	123.40	123.40	0.00	123.40	123.40	0.00
PBIDTM(%)	42.05	43.23	-2.74	42.05	43.23	-2.74	37.50	37.44	0.16

Jul, 2026

Thyrocare Tech. - Quaterly Results

The sales figure stood at Rs. 2256.60 millions for the June 2026 quarter. The mentioned figure indicates a growth of about 26.14% as compared to Rs. 1788.90 millions during the year-ago period.Good Net Profit growth of 39.17% reported above the corresponding previous quarter figure of Rs. 360.50 millions to Rs. 501.70 millioins.OP of the company witnessed a marginal growth to 791.20 millions from 604.80 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	2256.60	1788.90	26.14	2256.60	1788.90	26.14	7742.70	6331.00	22.30
Other Income	35.10	39.60	-11.36	35.10	39.60	-11.36	133.90	133.40	0.37
PBIDT	791.20	604.80	30.82	791.20	604.80	30.82	2697.20	2003.60	34.62
Interest	12.60	6.20	103.23	12.60	6.20	103.23	21.80	26.30	-17.11
PBDT	778.60	598.60	30.07	778.60	598.60	30.07	2615.70	1977.30	32.29
Depreciation	112.30	89.50	25.47	112.30	89.50	25.47	511.70	465.20	10.00
PBT	666.30	509.10	30.88	666.30	509.10	30.88	2104.00	1512.10	39.14
TAX	164.60	148.60	10.77	164.60	148.60	10.77	615.90	554.30	11.11
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	43.00	76.60	-43.86
PAT	501.70	360.50	39.17	501.70	360.50	39.17	1488.10	957.80	55.37
Equity	1591.70	529.90	200.38	1591.70	529.90	200.38	1591.70	529.90	200.38
PBIDTM(%)	35.06	33.81	3.71	35.06	33.81	3.71	34.84	31.65	10.07

Jul, 2026

Sanofi India informs about analyst meet

Sanofi India has informed that the Company will hold an investor / analysts call for an update on Unaudited Financial Results for the quarter and half year ended 30th June 2026, the details enclosed.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Sun Pharmaceutical Industries Ltd.	4,73,509 Crore
2	Divis Laboratories Ltd.	1,96,881 Crore
3	Torrent Pharmaceuticals Ltd.	1,90,832 Crore
4	Apollo Hospitals Enterprise Ltd.	1,27,149 Crore
5	Cipla Ltd.	1,13,894 Crore
6	Zydus Lifesciences Ltd.	1,10,523 Crore
7	Lupin Ltd.	1,10,189 Crore
8	Max Healthcare Institute Ltd.	1,08,476 Crore
9	Mankind Pharma Ltd.	1,05,357 Crore
10	Dr. Reddys Laboratories Ltd.	96,063 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,631	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,922	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,553	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,291	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,358	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,587	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,405	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,146	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,984	4,73,509	41.25	5.67	23.65	14.41

You have 8 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Senores Pharmaceutic - Quaterly Results

SMS Pharmaceuticals informs about board meeting

Akums Drugs’ arm gets nod to acquire Oriflame India’s manufacturing business

Novartis India - Quaterly Results

Thyrocare Tech. - Quaterly Results

Sanofi India informs about analyst meet

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.